Genprex, Inc. (GNPX): Nasdaq/NYSE listing notice — Genprex receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

Genprex, Inc.

Received Nasdaq letter on Aug 30, 2023 for failing Minimum Bid Price Requirement (bid <$1.00 for 30 consecutive trading days).
Granted 180 calendar days until Feb 26, 2024 to regain compliance by having bid >=$1.00 for 10 consecutive business days.
If not cured by Feb 26, may be eligible for extra 180-day period if meeting other listing standards and intends reverse split.
No immediate effect on listing; trading continues on Nasdaq Capital Market.
Company monitoring and assessing actions; no assurance of regaining compliance.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 30, 2023, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasd

View on SEC.gov

Browse all listing & compliance notices →

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-025064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.